Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer

Inclusion Criteria

• Men & women ≥20 years of age
• Histologically confirmed unresectable advanced or recurrent esophageal cancer
• Refractory to or intolerant of standard therapy
• ECOG Performance Status score 0 or 1
• A life expectancy of at least 3 months

Exclusion Criteria

• Current or past history of severe hypersensitivity to any other antibody products
• Patients with multiple primary cancers
• Patients with any metastasis in the brain or meninx that is symptomatic or requires treatment
• Patients with active, known or suspected autoimmune disease